81 – 90 of 154
- show: 10
- |
- sort: year (new to old)
Close
Embed this list
<iframe src=" "
width=" "
height=" "
allowtransparency="true"
frameborder="0">
</iframe>
- 2021
-
Mark
Clinical validity of second-generation tau PET tracers as biomarkers for Alzheimer’s disease in the context of a structured 5-phase development framework
(
- Contribution to journal › Scientific review
-
Mark
Clinical validity of increased cortical binding of tau ligands of the THK family and PBB3 on PET as biomarkers for Alzheimer’s disease in the context of a structured 5-phase development framework
(
- Contribution to journal › Scientific review
-
Mark
Tau PET correlates with different Alzheimer’s disease-related features compared to CSF and plasma p-tau biomarkers
(
- Contribution to journal › Article
-
Mark
Early stages of tau pathology and its associations with functional connectivity, atrophy and memory
(
- Contribution to journal › Article
-
Mark
Head-to-Head Comparison of 8 Plasma Amyloid-β 42/40 Assays in Alzheimer Disease
(
- Contribution to journal › Article
-
Mark
Neuroligin-1 in brain and CSF of neurodegenerative disorders : investigation for synaptic biomarkers
(
- Contribution to journal › Article
-
Mark
The impact of demographic, clinical, genetic, and imaging variables on tau PET status
(
- Contribution to journal › Article
-
Mark
Associations of Plasma Phospho-Tau217 Levels with Tau Positron Emission Tomography in Early Alzheimer Disease
(
- Contribution to journal › Article
-
Mark
Comparing the Clinical Utility and Diagnostic Performance of Cerebrospinal Fluid P-Tau181, P-Tau217 and P-Tau231 Assays
(
- Contribution to journal › Article
- 2020
-
Mark
Blood and cerebrospinal fluid neurofilament light differentially detect neurodegeneration in early Alzheimer's disease
(
- Contribution to journal › Article